Gilead Science Inc’s antiviral drug remdesivir was granted emergency use authorisation by the US Food and Drug Administration for COVID-19, clearing the way for broader use of the drug in more hospitals around the United States.
During a meeting in the Oval Office of the White House with President Donald Trump, Gilead Chief Executive Daniel O’Day called the move an important first step and said the company was donating 1.5 million vials of the drug to help patients.
The donation is expected to be enough for at least 140,000 patients, depending on the number of days they need to be treated.
Read full story here.
Dear visitor, the comments section is undergoing an overhaul and will return soon.